3rd Quarter - Report — THE NICKLES GROUP, LLC for UCB, INC. (2021)

Firm

THE NICKLES GROUP, LLC

Client

UCB, INC.

Income

$60,000

Expenses

—

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

S. 464 / H.R. 2163, the Safe Step Act and issues related to step therapy. Issues regarding FDA PDUFA procedures in COVID.

Lobbyist	Covered position, as disclosed
GREG D'ANGELO	—
MARY BETH SAVARY TAYLOR	—

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: S. 464 (117th), H.R. 2163 (117th)

Issues related to COVID-19 and access to Part B drugs; issues related to reimbursement of self-administered drugs; issues related to Part D drugs. Monitored issues related to Medicare sequestration. Issues related to value-based payment arrangements. Monitored issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S. 2164, the Lower Costs, More Cures Act. Monitored H.R. 3684, the Infrastructure Investment and Jobs Act, as it relates to drug pricing. H.R. 5376, the Build Back Better Act, as it relates to drug pricing.

Lobbyist	Covered position, as disclosed
GREG D'ANGELO	—
MARY BETH SAVARY TAYLOR	—

Contacted: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 19 (117th), H.R. 3684 (117th), H.R. 3 (117th), S. 2164 (117th), H.R. 5376 (117th)

Budget/Appropriations BUD

Monitored S.Con.Res.14, FY 2022 Budget Resolution.

Lobbyist	Covered position, as disclosed
GREG D'ANGELO	—
RACHEL JONES HENSLER	—
MARY BETH SAVARY TAYLOR	—

Contacted: Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE

Bills named: S.Con.Res. 14 (117th)

Government Issues GOV

Issues related to COVID-19 and access to Part B drugs, including issues related to reimbursement of self-administered drugs. Monitored issues related to P.L. 116-260, the Consolidated Appropriations Act of 2021. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R.19, the Lower Costs, More Cures Act. H.R. 2163, the Safe Step Act and issues related to step therapy. Monitored FY 2022 Budget Resolution. Monitored H.R. 3684, the Infrastructure Investment and Jobs Act, as it relates to drug pricing. H.R. 5376, the Build Back Better Act, as it relates to drug pricing.

Lobbyist	Covered position, as disclosed
BRETT BAKER	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 3684 (117th), H.R. 2163 (117th), H.R. 3 (117th), H.R. 5376 (117th), H.R. 19 (117th)

Taxation/Internal Revenue Code TAX

H.R. 5376, the Build Back Better Act, as it relates to orphan drug tax credit, corporate and international taxes.

Lobbyist	Covered position, as disclosed
RACHEL JONES HENSLER	—

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS)

Bills named: H.R. 5376 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.